Sanofi expects FY24 business EPS growth of at least a LSD percentage at CER
On October 21, 2024, the 2024 business EPS guidance was upgraded to growth of at least a low single-digit percentage at CER supported by the ...
Sanofi Profit Growth Beats Market View on Early Start of Vaccine Sales
Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...
Sanofi: Q3 Earnings Snapshot
PARIS (AP) — PARIS (AP) — Sanofi (SNY) on Friday reported third-quarter earnings of $3.09 billion. The company said it had net income of $1.23 per share. Earnings, adjusted for non-recurring costs, ...
Business Times6h
Sanofi profit lifted by early vaccine sales, Dupixent growth
Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.
Sanofi Q3 Profit Rises - Quick Facts
French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...
Sanofi Q3 earnings beat market view, boosted by vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...
Appian Appoints Americo Mazzotta as Vice President of EMEA Sales
Appian (Nasdaq: APPN), a leading enterprise platform for process orchestration and automation, is pleased to announce the ...
Sanofi enters exclusive talks with CD&R for Opella sale
PARIS (Reuters) -Sanofi said on Monday it had entered exclusive talks for the sale of a 50% controlling stake in its consumer ...
Sanofi reaches deal on terms of sale of consumer health arm, say French government sources
Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private ...
Sanofi to sell 51% stake in Opella to CD&R, 1% to BPI
France will take a stake in Sanofi's Opella through the Public Investment Bank (BPI), finance minister Antoine Armand said on ...